The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
Recruiting
Observational Study
Brest Cancer
Lung Cancer (NSCLC)
Pancreatic Cancer, Adult
Prostate Cancers
Ovarian Cancer
Colorectal Cancer
Glioblastoma (GBM)
Liver Carcinoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 40 – 75
- Sex
- Any
- Study type
- Observational
- Participants needed
- 6,000 (estimated)
- Sponsor
- Javier Toledo · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients. This two-phase, multi-center observational study aims to identify specific transcriptomic biomarkers in platelets and immune cells that distinguish cancer patients from healthy individuals and correlate with treatment outcome…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Phase 1 (Common Cancer Early Detection - CCANED)
Inclusion Criteria:
* Age: Adults aged 40 years or older.
* Confirmed diagnosis of one of the following common cancers: Non-Small Cell Lung Cancer (NSCLC), Glioblastoma Multiforme (GBM), Colorectal Cancer, Hepatocellular Carcinoma (HCC), Breast Canc…
Contacts